

Atty. Docket No. SEQ-4032-UT
USSN 10/607,806

REMARKS

In the Office Action, the Examiner has imposed a restriction requirement between Group I, drawn to a method for identifying a candidate therapeutic for fat reduction or alleviating NIDDM (claims 1-5 and 14-18), Group II, drawn to a method for reducing fat deposition in a subject (claims 11-13), and Group III, drawn to a method of reducing fat deposition in a subject and alleviating NIDDM in a subject (claims 6-10 and 19-23), for further prosecution on the merits.


Applicants elect the claims of Group I without traverse. Non-elected claims 6-13 and 19-23 are cancelled, without prejudice or disclaimer.

In the unlikely event the transmittal letter is separated from this document and the Office determines that an extension and/or other relief is required, Applicants petition for any required relief, including extensions of time, and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 503473**.

Respectfully submitted,

Dated: December 8, 2005

By:


Bruce Grant
Registration No. 47,608
for
Bruce D. Grant, A.P.C.
A California Corporation
for
BioTechnology Law Group
658 Marsolan Avenue
Solana Beach, CA 92075
Telephone: (858) 623-9470
Facsimile: (858) 623-9476